Cryoport to report Q2FY26 results on August 6

scanx
Reviewed by
Naman SScanX News Team
Key Highlights

Cryoport, Inc. will release its Q2 2026 financial results on August 6, 2026, followed by a conference call at 5:00 p.m. ET. The company will also publish a "Second Quarter 2026 in Review" document at 4:05 p.m. ET. Replays will be available online and via dial-in until August 13, 2026.

powered bylight_fuzz_icon
46368618

*this image is generated using AI for illustrative purposes only.

Cryoport, Inc., a global provider of integrated temperature-controlled supply chain solutions for the life sciences, will report its financial results for the second quarter ended June 30, 2026, on Thursday, August 6, 2026, after U.S. markets close. The announcement provides investors with an update on the company’s operational and financial performance for the period.

In addition to the earnings release, Cryoport will issue a document titled "Cryoport Second Quarter 2026 in Review" at 4:05 p.m. ET on the same day. This document offers a detailed review of financial and operational metrics and serves as a business update ahead of the management discussion.

Conference Call Details

Cryoport management will host a questions and answers conference call at 5:00 p.m. ET on August 6, 2026. The session will address inquiries from the investment community regarding the reported results, accompanied by a slide deck.

Detail Information
Date Thursday, August 6, 2026
Time 5:00 p.m. ET
Dial-in (U.S.) 1-800-717-1738
Dial-in (Intl) 1-646-307-1865
Conference ID 1142151

Investors are advised to allow 10 minutes prior to the call to download any necessary audio software. A live webcast will be available via the Investor Relations section of www.cryoportinc.com .

Replay Availability

The questions and answers call will be recorded and available approximately three hours after completion of the live event. The webcast replay will be accessible on the company’s website for a limited time. A dial-in replay will also be available until August 13, 2026. To access the dial-in replay, participants should call 1-844-512-2921 (United States) or 1-412-317-6671 (International) and enter the replay entry code: 1142151#.

About Cryoport, Inc.

Cryoport, Inc. (NASDAQ: CYRX) is headquartered in Nashville, Tennessee, with operations across the Americas, EMEA, and APAC. The company supports biopharmaceutical companies, contract manufacturers, and researchers with services including the Cryoportal Logistics Management Platform, advanced packaging, informatics, BioLogistics, biostorage, and cryopreservation services.

How will Cryoport's Q2 2026 results reflect the impact of recent expansions in its Cryoportal Logistics Management Platform on operational margins?

What specific growth drivers in the APAC and EMEA regions are management expected to highlight as key contributors to future revenue acceleration?

Will the earnings report indicate any shifts in customer demand patterns for biostorage and cryopreservation services amidst evolving biopharma R&D pipelines?

like20
dislike

Cryoport IntegriCell services selected for Verismo KIR-CAR programs

scanx
Reviewed by
Riya DScanX News Team
Key Highlights

Cryoport, Inc. announced that its IntegriCell cryopreservation services have been selected by Verismo Therapeutics to support its SynKIR-110 and SynKIR-310 multi-chain KIR-CAR programs. The candidates are in human clinical trials, with initial Phase 1 data presented at the American Association for Cancer Research (AACR) 2026 Annual Meeting.

powered bylight_fuzz_icon
43937810

*this image is generated using AI for illustrative purposes only.

Cryoport, Inc. announced that its IntegriCell cryopreservation services have been selected by Verismo Therapeutics to support its SynKIR-110 and SynKIR-310 multi-chain KIR-CAR programs. The partnership aims to advance Verismo's novel platform technology for treating solid tumors and B cell associated disorders. Initial Phase 1 data for both candidates were presented at the American Association for Cancer Research (AACR) 2026 Annual Meeting.

Verismo Therapeutics, a clinical-stage CAR T cell therapy company, is developing the multi-chain KIR-CAR platform. The SynKIR-110 candidate targets solid tumors, while SynKIR-310 focuses on B cell associated disorders and malignancies. Both programs are currently in human clinical trials.

Cryoport Systems' IntegriCell services will provide process development, technology transfer, and clinical cryopreservation support for these programs. The services are designed to ensure the integrity and viability of cell therapies throughout the supply chain.

The selection of IntegriCell underscores Cryoport's role in supporting advanced cell therapy trials. The company provides integrated temperature-controlled supply chain solutions for the life sciences industry.

Key Program Details

Program Target Indication Status
SynKIR-110 Solid tumors Human clinical trials
SynKIR-310 B cell associated disorders and malignancies Human clinical trials

What are the projected timelines for the next phases of clinical trials for SynKIR-110 and SynKIR-310?

How might this partnership influence Cryoport's market share in the cell therapy supply chain sector?

What are the potential regulatory challenges for Verismo's multi-chain KIR-CAR platform?

like17
dislike